SCHEMBL22637814

SCHEMBL22637814

CS(=O)(=O)Cc1cc(C(N)=NO)ccn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.42
POLB P06746 1/20 0.42
LMNA P02545 2/20 0.41
CYP3A4 P08684 2/20 0.41
KDM4E B2RXH2 1/20 0.41
TSHR P16473 1/20 0.41
GAA P10253 2/20 0.35
RAB9A P51151 2/20 0.35
RECQL P46063 1/20 0.35
KDM1A O60341 6/20 0.35
MBOAT4 Q96T53 1/20 0.33
F10 P00742 1/20 0.33
NPC1 O15118 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
ALOX15 P16050 1/20 0.33
HSD17B10 Q99714 1/20 0.33
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
GABRA1 P14867 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29478781 1.00 CYP1A2 (0.42) CYP1A2POLBLMNACYP3A4KDM4E
SCHEMBL22637811 1.00 CYP1A2 (0.42) CYP1A2POLBLMNACYP3A4KDM4E
SCHEMBL14993600 0.83 MBOAT4 (0.45) CYP1A2POLBLMNACYP3A4KDM4E
SCHEMBL26566973 0.78 GABRP (0.51) KDM4EMAPTGABRPGABRDGABRA1
SCHEMBL1727247 0.78 CYP1A2 (0.45) CYP1A2POLBLMNACYP3A4KDM4E
SCHEMBL1727246 0.78 CYP1A2 (0.45) CYP1A2POLBLMNACYP3A4KDM4E
SCHEMBL29478776 0.78 CYP1A2 (0.45) CYP1A2POLBLMNACYP3A4KDM4E
SCHEMBL22637872 0.76 CYP1A2 (0.44) CYP1A2POLBLMNACYP3A4KDM4E
SCHEMBL22637873 0.76 CYP1A2 (0.44) CYP1A2POLBLMNACYP3A4KDM4E
SCHEMBL29478771 0.76 CYP1A2 (0.44) CYP1A2POLBLMNACYP3A4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220259193-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2022-08-18 US disclosed
CN-114269340-A KCNT1 inhibitors and methods of use 普拉克西斯精密药物股份有限公司 2022-04-01 CN disclosed
EP-3962481-A1 KCNT1 INHIBITORS AND METHODS OF USE Praxis Precision Medicines, Inc. (US) 2022-03-09 EP disclosed
WO-2020227101-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2020-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220259193-A1 KCNT1 INHIBITORS AND METHODS OF USE KCNT1, KCNT2, KCNQ2 CYP1A2 3063/4885POLB 3959/4885LMNA 1423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.